FindTrial
Sign In

Effect of Vitamin D supplementation in treatment of First episode Psychosis

Effect of Vitamin D supplementation in treatment of First Episode Psychosis: A Randomised double blind, placebo controlled study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2017/07/009136
Enrollment
60
Registered
2017-07-27
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F23- Brief psychotic disorder Health Condition 2: null- First Episode PSychosis Health Condition 3: F323- Major depressive disorder, singleepisode, severe with psychotic features Health Condition 4: F302- Manic episode, severe with psychotic symptoms Health Condition 5: F200- Paranoid schizophrenia

Interventions

Intervention1: Vitamin D tablets: Vitamin D supplementation in dose of 2000 IU/day alongwith psychotropic medication Control Intervention1: Placebo tablet similar in shape, size, color, taste to activ

Sponsors

Central Institute of Psychiatry
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Either sex. 2. Age: 18-45 years. 3. Diagnosed cases of a. Schizophrenia (all subtypes) b. Mania with psychotic symptoms c. Severe Depression with psychotic symptoms d. Acute & Transient Psychotic Disorder ; fulfilling ICD-10 DCR (WHO, 1993) criteria. 4. Status of patient should be drug naïve (or drug free for minimum 4 weeks for oral psychotropic medications & 8 weeks for depot preparations). 5. Patients giving written informed consent.

Exclusion criteria

Exclusion criteria: 1. Presence of co-morbid psychiatric disorder. 2. Individuals with history of substance use meeting dependence criteria, other than nicotine & caffiene. 3. Co-morbid medical illness known to affect Vit.D level (Arthritis, Osteoporosis, Rickets, End Stage Renal Disease, Malabsorption Syndromes, Corticosteroid therapy). 4. Patients already on Vitamin D supplementation. 5. Patients receiving anticonvulsant medications as mood stabilizer. 6. Patients with BMI more than 30kg/m². 7. Menopausal females.

Design outcomes

Primary

MeasureTime frame
Brief Psychiatric rating scale, Positive and Negative Syndrome scale, Young Mania rating scale, Hamilton Rating scale for DepressionTimepoint: Baseline and at 4 weeks completion—

Secondary

MeasureTime frame
Serum Vitamin D levelTimepoint: Baseline and at 4 weeks completion—

Countries

India

Contacts

Public ContactDr Basudeb Das

Central Institute of Psychiatry, Ranchi, Jharkhand

basudeb71@gmail.com9431108544

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026